Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 30;26(7):3206.
doi: 10.3390/ijms26073206.

Strategies for Altering Delivery Technologies to Optimize CAR Therapy

Lili Cao  1 , Yingying Liu  2 , Guimei Lin  2
Affiliations
Review

Strategies for Altering Delivery Technologies to Optimize CAR Therapy

Lili Cao et al. Int J Mol Sci. .

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has been proven to be an effective strategy for the treatment of hematological malignancies. At present, how to prepare CAR-T cells efficiently, quickly, and safely is one of the urgent problems to be solved. The durability and activity of engineered T cells in solid tumors need to be further improved, and the strategy of T cells penetrating the tumor microenvironment also needs to be improved. In addition, although the problems mainly caused by T-cell biology are being solved, the manufacturing mode and process still need to be improved to ensure that CAR-T cell therapy can be widely used. This paper summarizes some strategies that can improve the efficacy of CAR-T cells.

Keywords: CAR-T cells; delivery vector; immunotherapy; solid tumor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Schematic representation of the optimized iterations of the chimeric antigen receptor structure for generations one to five.
Figure 2
Figure 2
Intracellular process of LNP as a carrier for transporting CAR cargo. Images were created with Figdraw.com. The image elements were acquired on 5 December 2023.
Figure 3
Figure 3
LNP expresses CAR at tumor sites through different drug-delivery pathways to achieve the goal of killing tumors. Images were created with Figdraw.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Larson R.C., Maus M.V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer. 2021;21:145–161. doi: 10.1038/s41568-020-00323-z. - DOI - PMC - PubMed
    1. MacKay M., Afshinnekoo E., Rub J., Hassan C., Khunte M., Baskaran N., Owens B., Liu L., Roboz G.J., Guzman M.L., et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 2020;38:233–244. doi: 10.1038/s41587-019-0329-2. - DOI - PubMed
    1. King A.C., Orozco J.S. Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma. J. Adv. Pract. Oncol. 2019;10:878–882. doi: 10.6004/jadpro.2019.10.8.9. - DOI - PMC - PubMed
    1. Irvine D.J., Maus M.V., Mooney D.J., Wong W.W. The future of engineered immune cell therapies. Science. 2022;378:853–858. doi: 10.1126/science.abq6990. - DOI - PMC - PubMed
    1. Ye B., Stary C.M., Li X., Gao Q., Kang C., Xiong X. Engineering chimeric antigen receptor-T cells for cancer treatment. Mol. Cancer. 2018;17:32. doi: 10.1186/s12943-018-0814-0. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources